Leflunomid Tillomed (Leflunomide)

Leflunomide is converted in the body to teriflunomide, an inhibitor of the enzyme dihydroorotate dehydrogenase. By blocking this key step in pyrimidine synthesis, the drug limits the proliferation of activated T‑ and B‑lymphocytes, thereby dampening the autoimmune response that drives joint inflammation.

The exact dose of Leflunomid Tillomed is set by the prescribing clinician based on the individual’s disease severity, prior treatment response, liver function, and overall health status. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Leflunomid Tillomed is classified as pregnancy category X, meaning it is contraindicated in pregnancy because of a high risk of fetal harm. It should not be used by women who are pregnant, planning to become pregnant, or breastfeeding. Effective contraception is required for women of child‑bearing potential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both leflunomide and methotrexate are conventional DMARDs used for inflammatory arthritis, but leflunomide is taken orally as a single daily tablet, whereas methotrexate may be oral or injectable and often requires weekly dosing. Leflunomide has a different safety profile, notably a higher risk of liver enzyme elevation and teratogenicity, while methotrexate is associated with mucosal and pulmonary toxicity.

Leflunomid Tillomed should be stored at ambient temperature, preferably below 25 °C, in its original packaging. The container should be kept away from moisture, direct sunlight, and excessive heat to maintain product stability throughout its shelf life.

Leflunomid Tillomed is administered orally, usually as a tablet taken with water. The exact timing (morning or evening) and whether it is taken with food depend on the prescribing physician’s instructions. Patients should swallow the tablet whole and not crush or split it unless directed.

The most serious risks include severe liver injury, bone‑marrow suppression leading to low blood counts, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should report any signs of jaundice, persistent fatigue, unexplained bruising, or severe rash to their healthcare provider promptly.

Leflunomid Tillomed is contraindicated in pregnant women, women planning pregnancy, and individuals with severe liver disease, active infections, or known hypersensitivity to leflunomide or its metabolites. Caution is also advised for patients with pre‑existing hematologic disorders or uncontrolled hypertension.